Journal
DRUG DISCOVERY TODAY
Volume 25, Issue 4, Pages 633-641Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2020.01.017
Keywords
-
Categories
Ask authors/readers for more resources
Glycogen synthase kinase-3 (GSK-3) regulates numerous signaling transductions and pathological states, from cell growth, inflammation, apoptosis, and heart failure to cancer. Recent studies have validated the feasibility of targeting GSK-3 beta for its therapeutic potential to maintain myocardial homeostasis. Herein, we review the multifactorial roles of GSK-3 beta in cardiac abnormalities, focusing primarily on recent investigations into myocardial survival. In addition, we discuss the cardioprotective potential of divergent GSK-3 beta inhibitors. Finally, we also highlight crosstalk between the various mechanisms underlying abnormal myocardial functions in which GSK-3 beta is involved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available